{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:36:03Z","timestamp":1785036963621,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10620-019-06016-4","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T12:34:21Z","timestamp":1577968461000},"page":"2986-2991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0221-7217","authenticated-orcid":false,"given":"Venkata R.","family":"Satyam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Hsuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansu","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmeel K.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"6016_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI, Herpes Z, Solomon CG. A 65-year-old man presents with a rash of 2\u00a0days\u2019 duration over the right forehead with vesicles and pustules, a few lesions on the right side and tip of the nose, and slight blurring of vision in the right eye. The rash was preceded by tingling in the area and is now associated with aching pain. How should this patient be evaluated and treated? N Engl J Med. 2013;369:255\u2013263. https:\/\/doi.org\/10.1056\/NEJMcp1302674.","journal-title":"N Engl J Med"},{"key":"6016_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","volume":"4","author":"G Gupta","year":"2006","unstructured":"Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483\u20131490. https:\/\/doi.org\/10.1016\/j.cgh.2006.09.019.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6016_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/apt.12182","volume":"37","author":"MD Long","year":"2013","unstructured":"Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420\u2013429. https:\/\/doi.org\/10.1111\/apt.12182.","journal-title":"Aliment Pharmacol Ther"},{"key":"6016_CR4","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1038\/ajg.2009.322","volume":"104","author":"J Marehbian","year":"2009","unstructured":"Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2009;104:2524\u20132533. https:\/\/doi.org\/10.1038\/ajg.2009.322.","journal-title":"Am J Gastroenterol"},{"key":"6016_CR5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","volume":"16","author":"N Khan","year":"2018","unstructured":"Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16:1919\u20131927.e3. https:\/\/doi.org\/10.1016\/j.cgh.2017.12.052.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6016_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","volume":"17","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn WJ, Pan\u00e9s J, D\u2019Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4\u00a0years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17:1541\u20131550. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.035.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6016_CR7","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1002\/ibd.22950","volume":"18","author":"G Cullen","year":"2012","unstructured":"Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2392\u20132403. https:\/\/doi.org\/10.1002\/ibd.22950.","journal-title":"Inflamm Bowel Dis"},{"key":"6016_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. Morb Mortal Wkly Rep. 2018;67:103\u2013108. https:\/\/doi.org\/10.15585\/mmwr.mm6703a5.","journal-title":"Morb Mortal Wkly Rep"},{"key":"6016_CR9","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087\u20132096. https:\/\/doi.org\/10.1056\/NEJMoa1501184.","journal-title":"N Engl J Med"},{"key":"6016_CR10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70\u00a0years of age or older. N Engl J Med. 2016;375:1019\u20131032. https:\/\/doi.org\/10.1056\/NEJMoa1603800.","journal-title":"N Engl J Med"},{"key":"6016_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/vaccines3020320","volume":"3","author":"A Di Pasquale","year":"2015","unstructured":"Di Pasquale A, Preiss S, Tavares Da Silva F, Gar\u00e7on N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines. 2015;3:320\u2013343. https:\/\/doi.org\/10.3390\/vaccines3020320.","journal-title":"Vaccines"},{"key":"6016_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1177\/0961203309345724","volume":"18","author":"E Israeli","year":"2009","unstructured":"Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18:1217\u20131225. https:\/\/doi.org\/10.1177\/0961203309345724.","journal-title":"Lupus"},{"key":"6016_CR13","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","volume":"31","author":"F Tavares Da Silva","year":"2013","unstructured":"Tavares Da Silva F, De Keyser F, Lambert PH, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine.. 2013;31:1870\u20131876. https:\/\/doi.org\/10.1016\/j.vaccine.2013.01.042.","journal-title":"Vaccine."},{"key":"6016_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent AM, Laup\u00e8ze B, Di Pasquale A, Hergli N, Collignon C, Gar\u00e7on N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines.. 2017;16:55\u201363. https:\/\/doi.org\/10.1080\/14760584.2016.1213632.","journal-title":"Expert Rev Vaccines."},{"key":"6016_CR15","unstructured":"Food and Drug Administration: Vaccines and Related Biological Products Advisory Committee. Briefing Document for HZ\/su (Zoster Vaccine Recombinant, Adjuvanted). Advisory Committee Meeting. https:\/\/www.fda.gov\/media\/107553\/download. Published 2017."},{"key":"6016_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"315","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. Lancet. 1980;315:514. https:\/\/doi.org\/10.1016\/S0140-6736(80)92767-1.","journal-title":"Lancet"},{"key":"6016_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.43.1.29","volume":"43","author":"RS Walmsley","year":"1998","unstructured":"Walmsley RS, Ayres RCS, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29\u201332. https:\/\/doi.org\/10.1136\/gut.43.1.29.","journal-title":"Gut"},{"key":"6016_CR18","unstructured":"Levinson W, Chin-Hong P, Joyce EA, Nussbaum J, Schwartz B. Overview of immunity. In: Review of medical microbiology and immunology: a guide to clinical infectious diseases, 15e. 15th ed. New York, NY: McGraw-Hill Education; 2018."},{"key":"6016_CR19","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/S1873-9946(13)60344-X","volume":"7","author":"W Sandborn","year":"2013","unstructured":"Sandborn W, Sands B, Rutgeerts P, et al. Sustained therapeutic benefit of vedolizumab throughout 1\u00a0year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial [abstract P323]. J Crohn\u2019s Colitis.. 2013;7:S138\u2013S139. https:\/\/doi.org\/10.1016\/S1873-9946(13)60344-X.","journal-title":"J Crohn\u2019s Colitis."},{"key":"6016_CR20","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54:922\u2013928. https:\/\/doi.org\/10.1093\/cid\/cir970.","journal-title":"Clin Infect Dis"},{"key":"6016_CR21","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271\u20132284. https:\/\/doi.org\/10.1056\/NEJMoa051016.","journal-title":"N Engl J Med"},{"key":"6016_CR22","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1016\/j.vaccine.2012.01.087","volume":"30","author":"SA Halperin","year":"2012","unstructured":"Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adult. Vaccine. 2012;30:2556\u20132563. https:\/\/doi.org\/10.1016\/j.vaccine.2012.01.087.","journal-title":"Vaccine"},{"key":"6016_CR23","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","volume":"31","author":"WL Heyward","year":"2013","unstructured":"Heyward WL, Kyle M, Blumenau J, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40\u201370\u00a0years of age. Vaccine.. 2013;31:5300\u20135305. https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.068.","journal-title":"Vaccine."},{"key":"6016_CR24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","volume":"36","author":"S Jackson","year":"2018","unstructured":"Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults q. Vaccine. 2018;36:668\u2013674. https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.038.","journal-title":"Vaccine"},{"key":"6016_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1177\/014107687907200908","volume":"72","author":"AD Langmuir","year":"1979","unstructured":"Langmuir AD. Guillain-Barr\u00e9 syndrome: the swine influenza virus vaccine incident in the United States of America, 1976\u201377: preliminary communication. J R Soc Med. 1979;72:660\u2013669. https:\/\/doi.org\/10.1177\/014107687907200908.","journal-title":"J R Soc Med"},{"key":"6016_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","volume":"110","author":"LB Schonberger","year":"1979","unstructured":"Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977. Am J Epidemiol.. 1979;110:105\u2013123.","journal-title":"Am J Epidemiol."},{"key":"6016_CR27","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/AJE\/KWS195","volume":"175","author":"SK Greene","year":"2012","unstructured":"Greene SK, Rett M, Weintraub ES, et al. Risk of Confirmed Guillain-Barr\u00e9 syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the vaccine safety datalink project, 2009\u20132010. Am J Epidemiol. 2012;175:1100. https:\/\/doi.org\/10.1093\/AJE\/KWS195.","journal-title":"Am J Epidemiol"},{"key":"6016_CR28","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/aje\/kws196","volume":"175","author":"ME Wise","year":"2012","unstructured":"Wise ME, Viray M, Sejvar JJ, et al. Guillain-Barr\u00e9 syndrome during the 2009\u20132010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol. 2012;175:1110\u20131119. https:\/\/doi.org\/10.1093\/aje\/kws196.","journal-title":"Am J Epidemiol"},{"key":"6016_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation. JAMA. 2019;322:123. https:\/\/doi.org\/10.1001\/jama.2019.9053.","journal-title":"JAMA"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-06016-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-06016-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-06016-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T01:03:15Z","timestamp":1609462995000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-06016-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["6016"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-06016-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"9 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Francis A. Farraye has served on advisory board for Glaxo Smith Kline. Venkata R. Satyam, Pei-Hsuan Li, Jason Reich, Taha Qazi, Ansu Noronha, Sharmeel K. Wasan declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}